Aduro is a clinical-stage cancer immunotherapy company with three products currently in human trials. The company’s lead candidate – an immunotherapy regimen combining their proprietary CRS-207 with GVAX Pancreas – is targeting metastatic pancreatic cancer and has received Breakthrough Therapy designation from the US Food and Drug Administration.

Research Grants 6 show all


$1.4M
2009

$200.7K
2010

$259.1K
2011

$763.5K
2012

$224.8K
2014

Publications 88 show all

  • 6
    CD8-Positive T-Lymphocytes/immunology
  • 5
    Neoplasms/immunology
  • 4
    Cancer Vaccines/therapeutic use
  • 4
    Listeria monocytogenes/immunology
  • 3
    Cancer Vaccines/immunology
  • 3
    Listeria monocytogenes/metabolism
  • 3
    Membrane Proteins/agonists
  • 3
    Membrane Proteins/metabolism
  • 3
    Tumor Microenvironment/immunology
  • 2
    Adjuvants, Immunologic/pharmacology

Patents 298show all

  • 126
    A61K - Preparations for medical, dental, or toilet purposes
  • 78
    C12N - Microorganisms or enzymes
  • 52
    C07K - Peptides
  • 28
    Y02A - Technologies for adaptation to climate change
  • 20
    C12Y - Enzymes
  • 7
    A61N - Electrotherapy
  • 7
    C07H - Sugars
  • 6
    C07D - Heterocyclic compounds
  • 6
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 3
    A01N - Preservation of bodies of humans or animals or plants or parts thereof

Clinical Trials 16show all

8Phase 26Phase 12Phase 1/Phase 2

SEC Filings show all


54
8-K

15
10-Q

9
D

5
10-K

1
S-1

Contact Information

626 Bancroft Way #3C
Berkeley, CA 94710
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$177,662,100101-2502015-04-15Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2011-04-20$16,200,000Series BMorningside Group
2008-05-15$3,900,000Series A
2011-12-05$512,100Debt Financing
2013-09-10$13,000,000Convertible Note
2015-04-15$25,000,000Post Ipo EquityNovartis
2014-06-11$55,700,000Series CJohnson & Johnson Development Corporation, Morningside Group
2015-01-05$51,400,000Series DFidelityForesite Capital, Janus Capital Group, Jennison Associates, Franklin Advisors, Clough Capital Partners, Morningside Group, OrbiMed
2009-11-03$1,175,000Series Unknown
2013-01-31$9,000,000Series B
2008-12-02$1,775,000Convertible Note

SEC Form D Funding Events

DateOfferedSoldType
2015-01-05$51,388,002$51,388,002Equity
2014-06-13$40,602,333$40,602,333Equity
2013-09-10$13,000,000$7,000,000Equity, Option to Acquire
2013-02-12$25,729,450$25,573,536Equity, Option to Acquire
2011-12-05$512,100$512,100Option to Acquire
2010-04-09$768,847$768,847Option to Acquire
2009-11-17$1,775,000$1,775,000Option to Acquire, Other
2009-11-17Indefinite$1,175,000Equity
2008-05-08Unknown Unknown Other (Paper Filing)

Key Executives

  • Stephen T. Isaacs
    Executive Officer, Director
  • S. David Model
    Executive Officer
  • David Fischell
    Director
  • William E. Gibson
    Director
  • Ross Haghighat
    Director
  • Rudy Mazzocchi
    Director
  • Christopher D. Ray
    Director
  • Dale H. Stevens
    Director
  • William Greenman
    Director
  • Drew Pardoll
    Director
  • Frank McCormick
    Director
  • Stephanie O'Brien
    Director
  • Stephen Isaacs
    Executive Officer, Director
  • Seth David Model
    Executive Officer
  • Gregory Schafer
    Executive Officer
  • Gerald David Chan
    Director
  • Jennifer Lew
    Executive Officer
  • Gregory W. Schafer
    Executive Officer
  • Thomas W. Dubensky
    Executive Officer
  • Dirk G. Brockstedt
    Executive Officer